1
|
Martínez Martín S, López-Estévez S, Foradada L, Kaur J, Serrano E, González-Larreategui Í, Giuntini F, Casacuberta-Serra S, Thabussot H, Castillo Cano V, Nonell L, Soucek L, Beaulieu M. Omomyc downregulates MYC transcriptional signature in preclinical models of solid tumours and shows long half-life in tumour tissue. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00918-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
2
|
González-Larreategui Í, Vera L, Giuntini F, Martínez-Martín S, Grueso J, López S, Serrano del Pozo E, Thabussot H, Macaya I, Beaulieu M, Vicent S, Casacuberta-Serra S, Soucek L. Characterization of KRAS-driven NSCLC cell lines with diverse mutational landscape and assessment of their response to MYC inhibition. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00925-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
3
|
Kaur J, Martínez-Martín S, Foradada L, López-Estévez S, Serrano E, Mártin-Fernández G, Thabussot H, Castillo Cano V, Casacuberta-Serra S, Zacarías-Fluck M, Grueso J, Beaulieu M, Whitfield J, Soucek L. MYC inhibition by Omomyc as a therapeutic strategy for (KRAS-mutated) colorectal cancer. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00866-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
4
|
Martorell L, Luce E, Vazquez JL, Richaud-Patin Y, Jimenez-Delgado S, Corrales I, Borras N, Casacuberta-Serra S, Weber A, Parra R, Altisent C, Follenzi A, Dubart-Kupperschmitt A, Raya A, Vidal F, Barquinero J. Advanced cell-based modeling of the royal disease: characterization of the mutated F9 mRNA. J Thromb Haemost 2017; 15:2188-2197. [PMID: 28834196 DOI: 10.1111/jth.13808] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2017] [Indexed: 11/28/2022]
Abstract
Essentials The Royal disease (RD) is a form of hemophilia B predicted to be caused by a splicing mutation. We generated an iPSC-based model of the disease allowing mechanistic studies at the RNA level. F9 mRNA analysis in iPSC-derived hepatocyte-like cells showed the predicted abnormal splicing. Mutated F9 mRNA level was very low but we also found traces of wild type transcripts. SUMMARY Background The royal disease is a form of hemophilia B (HB) that affected many descendants of Queen Victoria in the 19th and 20th centuries. It was found to be caused by the mutation F9 c.278-3A>G. Objective To generate a physiological cell model of the disease and to study F9 expression at the RNA level. Methods Using fibroblasts from skin biopsies of a previously identified hemophilic patient bearing the F9 c.278-3A>G mutation and his mother, we generated induced pluripotent stem cells (iPSCs). Both the patient's and mother's iPSCs were differentiated into hepatocyte-like cells (HLCs) and their F9 mRNA was analyzed using next-generation sequencing (NGS). Results and Conclusion We demonstrated the previously predicted aberrant splicing of the F9 transcript as a result of an intronic nucleotide substitution leading to a frameshift and the generation of a premature termination codon (PTC). The F9 mRNA level in the patient's HLCs was significantly reduced compared with that of his mother, suggesting that mutated transcripts undergo nonsense-mediated decay (NMD), a cellular mechanism that degrades PTC-containing mRNAs. We also detected small proportions of correctly spliced transcripts in the patient's HLCs, which, combined with genetic variability in splicing and NMD machineries, could partially explain some clinical variability among affected members of the European royal families who had lifespans above the average. This work allowed the demonstration of the pathologic consequences of an intronic mutation in the F9 gene and represents the first bona fide cellular model of HB allowing the study of rare mutations at the RNA level.
Collapse
Affiliation(s)
- L Martorell
- Gene and Cell Therapy Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain
- Congenital Coagulopathies Laboratory, Blood and Tissue Bank (BST), Barcelona, Spain
- Molecular Diagnosis and Therapy Unit, VHIR-UAB, Barcelona, Spain
| | - E Luce
- INSERM Unité Mixte de Recherche (UMR_S) 1193, Villejuif, France
- Université Paris-Sud, Villejuif, France
- Département Hospitalo-Universitaire Hepatinov, Paul Brousse Hospital, Villejuif, France
| | - J L Vazquez
- Center of Regenerative Medicine in Barcelona (CMRB), Barcelona, Spain
| | - Y Richaud-Patin
- Center of Regenerative Medicine in Barcelona (CMRB), Barcelona, Spain
| | - S Jimenez-Delgado
- Center of Regenerative Medicine in Barcelona (CMRB), Barcelona, Spain
| | - I Corrales
- Congenital Coagulopathies Laboratory, Blood and Tissue Bank (BST), Barcelona, Spain
| | - N Borras
- Congenital Coagulopathies Laboratory, Blood and Tissue Bank (BST), Barcelona, Spain
| | - S Casacuberta-Serra
- Gene and Cell Therapy Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - A Weber
- INSERM Unité Mixte de Recherche (UMR_S) 1193, Villejuif, France
- Université Paris-Sud, Villejuif, France
- Département Hospitalo-Universitaire Hepatinov, Paul Brousse Hospital, Villejuif, France
| | - R Parra
- Molecular Diagnosis and Therapy Unit, VHIR-UAB, Barcelona, Spain
- Hemophilia Unit, Vall d'Hebron University Hospital, Barcelona, Spain
| | - C Altisent
- Hemophilia Unit, Vall d'Hebron University Hospital, Barcelona, Spain
| | - A Follenzi
- University of Piemonte Orientale, Novara, Italy
| | - A Dubart-Kupperschmitt
- INSERM Unité Mixte de Recherche (UMR_S) 1193, Villejuif, France
- Université Paris-Sud, Villejuif, France
- Département Hospitalo-Universitaire Hepatinov, Paul Brousse Hospital, Villejuif, France
| | - A Raya
- Center of Regenerative Medicine in Barcelona (CMRB), Barcelona, Spain
- Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain
- Biomedical Research Networking Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid, Spain
| | - F Vidal
- Congenital Coagulopathies Laboratory, Blood and Tissue Bank (BST), Barcelona, Spain
- Molecular Diagnosis and Therapy Unit, VHIR-UAB, Barcelona, Spain
- Biomedical Research Networking Center on Cardiovascular Diseases, Madrid, Spain
| | - J Barquinero
- Gene and Cell Therapy Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain
| |
Collapse
|